Rapport Therapeutics, Inc. Common Stock
RAPP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Assets | – | – | – |
| Cash & Equivalents | $56,805 | $70,169 | $31,159 |
| Short-Term Investments | $248,475 | $77,309 | $0 |
| Receivables | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 |
| Other Curr. Assets | $4,522 | $3,394 | $109 |
| Total Curr. Assets | $309,802 | $150,872 | $31,268 |
| Property Plant & Equip (Net) | $4,971 | $4,000 | $335 |
| Goodwill | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 |
| Other NC Assets | $160 | $551 | $0 |
| Total NC Assets | $5,131 | $4,551 | $335 |
| Other Assets | $0 | $0 | $0 |
| Total Assets | $314,933 | $155,423 | $31,603 |
| Liabilities | – | – | – |
| Payables | $1,954 | $2,502 | $1,450 |
| Short-Term Debt | $737 | $670 | $0 |
| Tax Payable | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 |
| Other Curr. Liab. | $6,076 | $5,631 | $213 |
| Total Curr. Liab. | $8,767 | $8,803 | $1,663 |
| LT Debt | $739 | $1,476 | $10,435 |
| Deferred Rev, NC | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 |
| Other NC Liab. | $0 | $170,778 | $0 |
| Total NC Liab. | $739 | $172,254 | $10,435 |
| Other Liabilities | $0 | $0 | $0 |
| Cap. Leases | $1,476 | $2,146 | $0 |
| Total Liabilities | $9,506 | $181,057 | $12,098 |
| Equity | – | – | – |
| Pref Stock | $0 | $0 | $29,567 |
| Common Stock | $37 | $4 | $31 |
| Retained Earnings | -$123,745 | -$45,438 | -$10,652 |
| AOCI | -$522 | $4 | $0 |
| Other Equity | $429,657 | $19,796 | $559 |
| Total Equity | $305,427 | -$25,634 | $19,505 |
| Supplemental Information | – | – | – |
| Minority Interest | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $314,933 | $155,423 | $31,603 |
| Net Debt | -$55,329 | -$68,023 | -$20,724 |